PLD2 and cancer: In particular for cancer, some therapeutics, for example, VEGFR tyrosine kinase inhibitors, are independently associated with a substantially elevated risk of hypertension development48, and thus use of a PLD2 inhibitor in parallel with them could result in synergistic adverse effects.